Latest Updates

SOCMA Seeks Member Input on Chinese-origin Medical-Care Products

The Office of the U.S. Trade Representative (USTR) has announced that USTR is requesting public comments by June 25, 2020 on further modifications to remove Section 301 duties from additional Chinese-origin medical-care products, including pharmaceuticals and chemicals to make pharmaceuticals. SOCMA will submit comments to the docket and as such, requests input from members via the SOCMA 301 COVID-19 Data Sheet (page 3) for inclusion in SOCMA 301 COVID-19 Comments.

March 31, 2020

Cambrex Appoints Troy Player as President, Early Stage Development & Testing Business Unit

Cambrex, the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that Troy Player has been appointed as President, Early Stage Development and Testing (ESDT). In his new role, he has responsibility for operations at the Agawam, Massachusetts; Durham, North Carolina; Edinburgh, UK; High Point, North Carolina and Longmont, Colorado facilities.

March 31, 2020

Multi Industry Letter Supporting DHS CISA Critical Infrastructure Guidance

Coalition letter to President and other elected officials urging coordinated actions of: 1) adopted definition of "critical infrastructure" as currently defined by DHS, 2) no artificial barriers to transportation of critical manufactured goods, and 3) assurance that critical workforce are not impeded by curfew to get to and from facilities.

March 25, 2020

OSHA Regulations and COVID-19

The following guidance addresses OSHA health and safety regulatory requirements related to the current COVID-19 pandemic.

March 24, 2020